Global Tubeless Insulin Pump Market By Type (Disposable Patch Pumps, Reusable Patch Pumps) By Application (Type 1 Diabetes, Type 2 Diabetes) By End User ( Hospitals, Homecare, Diabetes Clinics, Ambulatory Surgical Centers, Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Report Overview

Global Tubeless Insulin Pump Market size is expected to be worth around US$ 15.2 Billion by 2035 from US$ 2.9 Billion in 2025, growing at a CAGR of 18.1% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 45.9% share with a revenue of US$ 1.3 Billion.

The global tubeless insulin pump market is witnessing notable growth due to the increasing prevalence of diabetes and the growing demand for convenient insulin delivery systems. Tubeless insulin pumps, also referred to as insulin patch pumps, are compact, lightweight, and wearable devices designed to deliver continuous subcutaneous insulin infusion without the need for external tubing.

These devices provide enhanced flexibility, discreet usage, and improved patient comfort compared to conventional insulin pumps. Advanced technologies such as Nitinol wire systems, spring-based mechanisms, piezoelectric crystals, step motors, and manual pumping chambers are increasingly being integrated into modern tubeless insulin pumps to improve insulin delivery accuracy and patient safety.

The rising burden of diabetes remains a key factor supporting market expansion. According to the Centers for Disease Control and Prevention (CDC), approximately 30.3 million people in the United States were living with diabetes in 2015, representing nearly 9.4% of the total population. Furthermore, the CDC reported that nearly 25% of adults aged 65 years and older were affected by diabetes, highlighting the growing disease burden among the geriatric population. Recent CDC estimates indicate that nearly 40.1 million Americans had diabetes in 2023, demonstrating the continuous rise in disease prevalence.

Growing preference for user-friendly diabetes management devices is also accelerating the adoption of tubeless insulin pumps. According to the National Center for Biotechnology Information (NCBI), continuous subcutaneous insulin infusion systems improve glycemic control and enhance quality of life among patients with type 1 diabetes.

In addition, a multicenter study published on PubMed involving 156 adults with type 1 diabetes demonstrated significant improvement in HbA1c levels following the transition to tubeless insulin pump therapy. The integration of continuous glucose monitoring (CGM) systems with advanced platforms such as Omnipod DASH® and myDiabby Healthcare® Data Management Platform is further strengthening market growth by enabling real-time glucose monitoring and optimized insulin delivery.

Key Takeaways

• Market Size: Global Tubeless Insulin Pump Market size is expected to be worth around US$ 15.2 Billion by 2035 from US$ 2.9 Billion in 2025.
• Market Share: The market growing at a CAGR of 18.1% during the forecast period from 2026 to 2035.
• Type Analysis: Disposable Patch Pumps accounted for the largest market share of 56.2% in 2025,
• Application Analysis: Type 1 Diabetes dominated the market with a 64.2% share in 2025.
• End User Analysis: Homecare emerged as the leading segment, accounting for 42.5% of the global market share in 2025.
• Regional Analysis: In 2025, North America led the market, achieving over 45.9% share with a revenue of US$ 1.3 Billion.

Type Analysis

The tubeless insulin pump market is segmented into Disposable Patch Pumps and Reusable Patch Pumps. Disposable Patch Pumps accounted for the largest market share of 56.2% in 2025, primarily due to their ease of use, compact design, and reduced maintenance requirements. These pumps are designed for single-use applications, eliminating the need for frequent cleaning and lowering the risk of contamination and device-related complications. Growing preference among diabetic patients for convenient and minimally invasive insulin delivery systems has significantly supported segment expansion.

In addition, increasing adoption of wearable healthcare technologies and rising awareness regarding continuous insulin management have accelerated demand for disposable systems. Manufacturers are also introducing advanced disposable pumps integrated with continuous glucose monitoring (CGM) technologies, further enhancing patient compliance and treatment efficiency.

Reusable Patch Pumps represent the second major segment and are witnessing stable growth owing to their long-term cost advantages and environmentally sustainable design. These pumps utilize reusable electronic components combined with replaceable insulin reservoirs, making them economical for long-duration therapy. Increasing technological advancements, including smartphone connectivity and automated insulin delivery functions, are expected to support future segment growth across developed healthcare markets.

Application Analysis

Based on application, the tubeless insulin pump market is segmented into Type 1 Diabetes and Type 2 Diabetes. Type 1 Diabetes dominated the market with a 64.2% share in 2025, driven by the high dependence of patients on continuous insulin therapy for effective glucose management.

Tubeless insulin pumps are increasingly preferred among Type 1 diabetic patients due to their ability to provide accurate basal and bolus insulin delivery while improving patient mobility and lifestyle convenience. The growing prevalence of Type 1 diabetes among children, adolescents, and young adults has further accelerated adoption rates globally. Moreover, favorable reimbursement policies and increasing integration of continuous glucose monitoring systems with insulin pumps are contributing to widespread utilization within this segment.

The Type 2 Diabetes segment is also experiencing significant growth owing to the rising global diabetic population and increasing awareness regarding advanced insulin management solutions. Patients with insulin-dependent Type 2 diabetes are increasingly shifting toward tubeless pumps to improve glycemic control and reduce the burden associated with multiple daily injections.

Expanding healthcare expenditure, technological innovations, and increasing physician recommendations for automated insulin delivery systems are expected to support long-term segment expansion, particularly across emerging economies with improving diabetes care infrastructure.

End User Analysis

Based on end user, the tubeless insulin pump market is segmented into Homecare, Hospitals, Diabetes Clinics, Ambulatory Surgical Centers, and Others. Homecare emerged as the leading segment, accounting for 42.5% of the global market share in 2025. The dominance of this segment is primarily attributed to the increasing preference for self-management of diabetes and the growing adoption of home-based healthcare solutions.

Tubeless insulin pumps offer enhanced convenience, portability, and ease of operation, making them highly suitable for homecare settings. Rising patient awareness regarding continuous glucose monitoring and personalized insulin delivery has further accelerated demand for these devices in homecare environments. Additionally, technological advancements enabling remote monitoring and smartphone integration are improving treatment adherence and patient outcomes.

Hospitals represent a significant segment owing to increasing utilization of advanced insulin delivery systems for inpatient diabetes management and post-diagnosis treatment support. Diabetes Clinics are also witnessing notable growth due to the rising number of specialized diabetes care centers offering customized insulin therapy programs.

Ambulatory Surgical Centers are gradually adopting tubeless insulin pumps for perioperative glucose management and outpatient procedures. The Others segment includes long-term care facilities and specialty healthcare centers contributing to overall market expansion.

Key Market Segments

By Type

• Disposable Patch Pumps
• Reusable Patch Pumps

By Application

• Type 1 Diabetes
• Type 2 Diabetes

By End User

• Hospitals
• Homecare
• Diabetes Clinics
• Ambulatory Surgical Centers
• Others

Driving Factors

Rising diabetes burden and technology adoption
Rising global diabetes prevalence is the primary driver for tubeless insulin pump adoption, as health systems seek more effective long-term glycemic control tools. The World Health Organization reports that the number of people living with diabetes has increased from about 200 million in 1990 to 830 million in 2022, with faster growth in low- and middle-income countries, directly expanding the eligible patient pool for advanced insulin delivery.

The International Diabetes Federation estimates 537 million adults with diabetes in 2021, projected to 643 million by 2030 and 783 million by 2045, underscoring sustained demand for intensive insulin therapy technologies. In the U.S. alone, around 40.1 million people were living with diagnosed or undiagnosed diabetes in 2023, or 12% of the population, creating a large addressable market for pumps.

Real-world data show that approximately 73–76% of type 1 diabetes patients in a large U.S. cohort used insulin pumps between 2017 and 2020, validating growing clinical acceptance of pump-based therapy that supports faster transition from tubed to tubeless systems.

Trending Factors

Shift to wearable, connected, and home-based care
A key trend in the tubeless insulin pump market is the shift toward fully wearable, connected devices integrated with continuous glucose monitoring (CGM) and smartphone ecosystems to support home-based diabetes management. Recent systems combine tubeless pumps with CGM and Bluetooth connectivity, enabling automated insulin delivery based on real-time sensor glucose, which aligns with broader digital health policies encouraging remote monitoring and telehealth follow-up.

Clinical data from cloud-connected tubeless pump platforms show that patients with type 1 or type 2 diabetes can maintain tighter glucose ranges across age groups when supported by continuous data sharing and algorithm-guided dosing, reinforcing demand for interoperable devices.

Global diabetes prevalence projections—589 million adults living with diabetes today and 853 million by 2050—are pushing healthcare providers to adopt scalable, technology-enabled models, where wearable pumps play a central role. This trend is further reinforced by national guidelines in many countries that promote self-management and structured education, making compact, discreet, tubeless pumps attractive for younger and working-age populations who require flexible, all-day wear.

Restraining Factors

High costs, access gaps, and technical complexity
Despite strong demand drivers, high device and consumable costs remain a major restraint on tubeless insulin pump uptake, particularly in low- and middle-income countries where diabetes is rising fastest. WHO notes that more than half of people with diabetes worldwide were not receiving medication treatment in 2022, highlighting affordability and access barriers that also affect advanced devices like pumps.

Even in high-income markets such as the United States, 40.1 million people had diabetes in 2023 but reimbursement policies, co-payments, and coverage variability limit widespread pump use, especially among uninsured or under-insured groups. Early experience with insulin infusion pumps documented safety concerns, including hypoglycemia-related deaths in some intensively treated patients, which led public-health agencies to call for careful monitoring, robust training, and clear risk-benefit assessment.

These historical safety issues continue to inform regulatory expectations for tubeless designs, including requirements for sophisticated algorithms, alarms, and quality systems, increasing development complexity and cost for manufacturers and potentially slowing approvals in some jurisdictions.

Opportunity

Personalized, preventative and emerging-market diabetes care
The largest opportunity for the tubeless insulin pump market lies in personalized diabetes care strategies and expansion into emerging markets where diabetes prevalence is accelerating. IDF data show 537 million adults living with diabetes in 2021, projected to 783 million by 2045, while an additional 541 million people already have impaired glucose tolerance, many of whom will progress to diabetes at an estimated 5–10% per year.

This funnel of high-risk individuals creates demand for earlier, individualized intervention, where adjustable basal-bolus profiles and data-driven dosing from tubeless pumps can reduce complications and hospitalization rates. National diabetes programs and registries are increasingly using large-scale datasets to stratify risk and guide reimbursement, opening pathways to targeted funding for high-benefit technologies, including wearable pumps for type 1 and insulin-intensive type 2 patients.

As low- and middle-income countries experience faster growth in diabetes prevalence than high-income countries, policy makers are prioritizing home-based management models, telemedicine, and digital therapeutics, positioning affordable tubeless pumps integrated with mobile health platforms as a key lever to manage resource constraints.

Regional Analysis

In 2025, North America dominated the Tubeless Insulin Pump market, accounting for over 45.9% of the global market share and generating revenue of approximately US$ 1.3 billion. The regional market growth has been primarily driven by the rising prevalence of diabetes, increasing adoption of advanced insulin delivery technologies, and strong healthcare infrastructure across the United States and Canada. The growing preference for wearable and minimally invasive diabetes management solutions has significantly accelerated the demand for tubeless insulin pumps in the region.

In addition, favorable reimbursement policies, higher healthcare expenditure, and strong awareness regarding continuous glucose monitoring and insulin pump therapy have supported market expansion. The presence of leading market players, ongoing technological innovations, and increasing investments in digital healthcare solutions have further strengthened North America’s position in the market. The integration of smart insulin delivery systems with mobile applications and real-time glucose monitoring devices has also enhanced patient convenience and treatment efficiency.

Moreover, the increasing adoption of automated insulin delivery systems among pediatric and adult diabetic populations is expected to continue supporting regional market growth. The market is anticipated to maintain steady expansion over the forecast period owing to continuous product advancements, growing patient awareness, and supportive regulatory approvals for next-generation diabetes management devices.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Players Analysis

The Tubeless Insulin Pump market is highly competitive, with leading players focusing on product innovation, technological integration, and geographic expansion to strengthen their market presence. Major companies operating in the market include Insulet Corporation, Roche, Medtrum Technologies, Terumo Corporation, and MannKind Corporation. These companies collectively account for a significant share of the global market due to their strong product portfolios and extensive distribution networks.

Insulet Corporation remains the dominant market participant through its Omnipod platform, supported by continuous product enhancements and strong adoption across North America and Europe. Meanwhile, Roche and Terumo Corporation are strengthening their positions through digital health integration and advanced wearable insulin delivery solutions.

Emerging players such as CeQur and Debiotech are also expanding through R&D investments and strategic collaborations, intensifying competition and driving innovation across the global tubeless insulin pump market.

Market Key Players

• Insulet Corporation
• Medtronic plc
• Tandem Diabetes Care, Inc.
• EOFlow Co., Ltd.
• Valeritas, Inc.
• Roche Holding AG
• Cellnovo Group SA
• Johnson & Johnson
• SOOIL Development Co., Ltd.
• MicroPort Scientific Corporation
• SFC Fluidics, LLC
• Bigfoot Biomedical, Inc.
• Beta Bionics, Inc.
• Diabeloop SA
• Admetsys Corporation
• Others

Recent Developments

• Insulet Corporation (March 2025): Announced the international expansion of its Omnipod 5 automated insulin delivery system across Australia, Belgium, Canada, and Switzerland. The development strengthened the company’s global footprint in the tubeless insulin pump segment and increased patient access to advanced diabetes management technologies. The launch also expanded compatibility with Dexcom and Abbott continuous glucose monitoring systems, improving therapy flexibility for users with Type 1 diabetes.
• Medtronic (September 2025): Received U.S. FDA clearance for integration between its MiniMed 780G system and Abbott’s Instinct sensor platform. The approval also expanded the system’s indication for adults with insulin-requiring Type 2 diabetes. The development reflected increasing competition in advanced automated insulin delivery technologies and reinforced industry movement toward interoperable diabetes ecosystems.
• Renu MedTech (November 2025): Introduced InsuPatch, a tubeless insulin patch pump developed specifically for the Indian market. The company positioned the product as India’s first affordable patch-style insulin infusion pump, reflecting increasing regional investments in localized and cost-effective diabetes technologies. The launch is expected to improve accessibility to tubeless insulin delivery systems in emerging economies.
• Insulet Corporation (December 2025): Received FDA 510(k) clearance for major algorithm upgrades to the Omnipod 5 system. The enhancements included a new 100 mg/dL glucose target setting and improved automated insulin delivery functions designed to simplify patient experience and improve glycemic control. The development represented a significant product innovation milestone in the tubeless insulin pump market

Report Scope